OPTHEA LIMITED

0.00%

60.0¢

Market Cap $738.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Latest Threads

Tag

Subject

OPT

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

31/07/25

2.8K

31/07/25

Last post Macrosoft

2.8K

OPT

Ann: Long Term Suspended Entities

23/07/25

2.6K

23/07/25

Last post TONFRA

2.6K

OPT

Defamation Against Opthea Will Be Reported

23/07/25

24K

23/07/25

Last post Maverick1975

24K

OPT

Ann: Opthea Announces COAST Phase 3 Trial Topline Results

10 11 12

21/07/25

665

242K

21/07/25

Last post Rgupta11in

665

242K

OPT

AFR: Phil King’s Regal writes Opthea to zero and backs off risky bets

09/07/25

6.2K

09/07/25

Last post FreeFromStyle

6.2K

OPT

Ann: Details of Company Address

07/07/25

1.0K

07/07/25

Last post Macrosoft

1.0K

OPT

The DFA Discussion

29/06/25

105

46K

29/06/25

Last post Ollie3039

105

46K

OPT

Ann: Opthea Announces Decision to Discontinue Wet AMD Trials

2 3

26/06/25

167

95K

26/06/25

Last post slambo

167

95K

See All Discussions

Timeline

Quarterly Activities/Appendix 4C Cash Flow Report
30 Jul 08:29	Share

Long Term Suspended Entities
16 Jul 16:15	Share

Details of Company Address
04 Jul 13:18	Share

Final Director's Interest Notice Quinton Oswald
02 Jun 09:14	Share

Final Director's Interest Notice Dr Susan Orr
02 Jun 09:13	Share

Final Director's Interest Notice Dr Julia Haller
02 Jun 09:13	Share

Final Director's Interest Notice Anshul Thakral
02 Jun 09:13	Share

Opthea Provides Corporate Update
02 Jun 08:44	Share

Ceasing to be a substantial holder
12 May 08:10	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 08:53	Share

Opthea Provides Corporate Update
10 Apr 09:21	Share

Continuation of Suspension from Quotation
31 Mar 12:44	Share

Opthea Announces Decision to Discontinue Wet AMD Trials
31 Mar 12:41	Share

Becoming a substantial holder
31 Mar 08:17	Share

Ceasing to be a substantial holder
25 Mar 08:18	Share

Opthea Announces COAST Phase 3 Trial Topline Results
24 Mar 10:41	Share

Voluntary suspension
19 Mar 09:36	Share

Trading Halt
17 Mar 08:41	Share

Becoming a substantial holder
14 Mar 19:28	Share

Application for quotation of securities - OPT
14 Mar 16:13	Share

Application for quotation of securities - OPT
14 Mar 16:10	Share

Update - Application for quotation of securities - OPT
14 Mar 13:22	Share

Application for quotation of securities - OPT
11 Mar 13:18	Share

Application for quotation of securities - OPT
11 Mar 13:17	Share

Opthea Announces Phase 2b Wet AMD Publication
03 Mar 08:22	Share

Opthea Reports Half Year Results and Business Updates
28 Feb 08:22	Share

Opthea Half Year Financial Report - Appendix 4D
28 Feb 08:21	Share

Opthea Completes Drug Product PPQ Campaign
26 Feb 08:06	Share

Application for quotation of securities - OPT
21 Feb 16:53	Share

Application for quotation of securities - OPT
21 Feb 16:52	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $738.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED

Latest Threads

Redcastle Resources Delivers Positive Scoping Study for Queen Alexandra

Timeline

Featured News

Latest Articles

Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce reduction of -65%.

Opthea's Phase 3 trial results fail to help patients, future of company at risk

It mightn't be too surprising that Opthea applied for a voluntary suspension last week ahead of Monday's Phase 3 trial results.

Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper

Opthea has jumped to 77cps after having its diabetic eye drug of interest further validated as a potential treatment in a scientific paper.

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

Featured News